References
- Pitout JD, Gregson DB, Church DL, Elsayed S, Laupland KB. Community-wide outbreaks of clonally related CTX-M-14 beta-lactamase-producing Escherichia coli strains in the Calgary health region. J Clin Microbiol 2005; 43: 2844–9
- Jernelius H, Zbornik J, Bauer CA. One or 3 weeks treatment of acute pyelonephritis? A double blend comparison, using a fixed combination of pivampicillin plus pivmecillinam. Acta Med Scand 1988; 223: 469–77
- Helin I. Pivmecillinam in the treatment of childhood pyelonephritis. J Int Med Res 1983; 11: 113–5
- Cronberg S, Banke S, Bruno AM, Carlsson M, Elmrud H, Elowsson S, et al. Ampicillin plus mecillinam vs cefotaxime/cefadroxil treatment of patients with severe pneumonia or pyelonephritis: a double-blind multicentre study evaluated by intention-to-treat analysis. Scand J Infect Dis 1995; 27: 460–3
- Thomas K, Weinbren MJ, Warner M, Woodford N, Livermore D. Activity of mecillinam against ESBL producers in vitro. Jour Antimicrob Chemother 2006; 57: 367–8
- Mulvey MR, Bryce E, Boyd D, Ofner-Agostini M, Christianson S, Simor AE, Paton S. Ambler class A extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella spp. in Canadian hospitals. Antimicrob Agents Chemother 2004; 48: 1204–14
- Holme E, Greter J, Jacobson CE, Lindstedt S, Nordin I, Kristiansson B, Jodal U. Carnitine deficiency induced by pivampicillin and pivmecillinam therapy. Lancet 1989; 26: 469–73